FDA Approves the First mRNA Seasonal Flu Vaccine for Adults 50 and Older

The Food and Drug Administration approved Moderna's mFLUSIVA, the first U.S. seasonal influenza vaccine based on messenger RNA technology. The product is indicated for adults age 50 and older; patients should use the FDA label and their clinician's advice to determine whether it is appropriate for them.

What makes this approval genuinely unusual isn't the science, it's the road it took to get there. Earlier this year, the FDA declined to even review Moderna's application at all, a rare move against a large pharmaceutical company that had run a substantial, largely favorable clinical trial. The agency only relented after real pushback from the pharmaceutical industry and public health experts, eventually convening a meeting of independent outside advisers in June before ultimately clearing the vaccine two months later.

The policy debate around the vaccine

The FDA's initial refusal to review the application didn't happen in a vacuum. It came amid a broader climate of hostility toward mRNA technology within the current administration, with Health and Human Services Secretary Robert F. Kennedy Jr., a longtime vaccine critic, repeatedly condemning mRNA vaccines publicly. The administration has also cut funding for mRNA vaccine research more broadly and scaled back access to COVID vaccines during the same stretch, part of a wider backlash against pandemic-era vaccine mandates that spilled over into skepticism of the underlying technology itself.

Against that backdrop, the eventual approval reads as a genuine reversal rather than a routine regulatory milestone. Moderna CEO Stéphane Bancel framed it as proof of the continued strength and versatility of the company's mRNA platform, calling it an important new option for older Americans navigating a persistent public health challenge.

What the trial data shows

Company research covering more than 40,000 participants found mFLUSIVA to be safe and, notably, associated with stronger protection than traditional flu vaccines, according to trial results shared with regulators. That protection matters given how severe recent flu seasons have been: the 2024-2025 season alone was linked to an estimated 45,000 deaths in the US, with flu-related hospitalizations and outpatient visits reaching their highest levels in fifteen years, according to the Centers for Disease Control and Prevention.

Experts are careful to frame mFLUSIVA as an additional option rather than a wholesale replacement for existing flu vaccines. Dr. Georges Benjamin, chief executive of the American Public Health Association, pointed to a different advantage entirely: mRNA vaccines don't rely on the decades-old process of growing vaccine virus in chicken eggs, a method that limits how quickly manufacturers can respond when a flu strain shifts unexpectedly. He said the technology could eventually let public health officials adjust to emerging flu strains far faster than the current system allows.

Potential advantages of the mRNA platform

Moderna has floated an even bigger long-term implication: the speed of mRNA vaccine production could eventually end the practice of selecting a single flu strain for an entire hemisphere each season, a system that's been the global norm for decades. In theory, individual countries could instead pick whichever strain match works best for their own population in real time, rather than committing to one forecasted strain many months in advance across an entire hemisphere.

For now, mFLUSIVA is expected to be available within weeks, in time for the 2026-2027 respiratory virus season. Whether the vaccine's arrival marks a genuine turning point for mRNA technology in the US, or simply one approval within a still-contentious regulatory and political environment, will likely depend on how the accelerated approval for older adults holds up once the required follow-up data comes in.